Robert J. Slack

Galecto (Denmark) — Denmark

Immunology and Microbiology · Life Sciences

28h-index2.9kcitations114works6.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Galectins and Cancer Biology(33), Cell Adhesion Molecules Research(19), Synthesis and Reactions of Organic Compounds(14), Synthesis and Characterization of Heterocyclic Compounds(13), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis(11)

Publications114 total

Pharmacological Characterization of GB1908, a Selective Galectin-1 Carbohydrate Binding Domain Inhibitor for the Treatment of Cancer
Pharmacology·2025· 3 cited
Development and Characterization of a High-Affinity Selective Galectin-3 Mouse Tool Compound in Mouse Models of Cancer
Journal of Medicinal Chemistry·2024· 2 cited
Effect of GB1107, a novel galectin-3 inhibitor on pro-fibrotic signalling in the liver
European Journal of Pharmacology·2024· 10 cited
Galectin-1 Induces the Production of Immune-Suppressive Cytokines in Human and Mouse T Cells
International Journal of Molecular Sciences·2024· 4 citedOpen Access
Core Modifications of GSK3335103 toward Orally Bioavailable α<sub>v</sub>β<sub>6</sub> Inhibitors with Improved Synthetic Tractability
Journal of Medicinal Chemistry·2024· 4 cited
Single‑Dose Pharmacokinetics and Safety of the Oral Galectin‑3 Inhibitor, Selvigaltin (GB1211), in Participants with Hepatic Impairment
Clinical Drug Investigation·2024· 7 cited
Discovery and Development of Highly Potent and Orally Bioavailable Nonpeptidic α<sub>v</sub>β<sub>6</sub> Integrin Inhibitors
Journal of Medicinal Chemistry·2024· 1 cited
Relative bioavailability and food effect of the galectin-3 inhibitor selvigaltin (GB1211) administered as a tablet in healthy participants (GALBA-1)
Cancer Chemotherapy and Pharmacology·2024· 2 citedOpen Access
The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis
Frontiers in Pharmacology·2024· 9 citedOpen Access
A Quantitative Human Red Blood Cell Agglutination Assay for Characterisation of Galectin Inhibitors
International Journal of Molecular Sciences·2024Open Access
Determining the Affinity and Kinetics of Small Molecule Inhibitors of Galectin-1 Using Surface Plasmon Resonance
International Journal of Molecular Sciences·2024· 1 citedOpen Access
Discovery of the Selective and Orally Available Galectin-1 Inhibitor GB1908 as a Potential Treatment for Lung Cancer
Journal of Medicinal Chemistry·2024· 26 citedOpen Access
A Quantitative Human Red Blood Cell Agglutination Assay for Characterisation of Galectin Inhibitors
Preprints.org·2024· 1 citedOpen Access
Defining the mechanism of galectin-3–mediated TGF-β1 activation and its role in lung fibrosis
Journal of Biological Chemistry·2024· 24 citedOpen Access
Determining the Affinity and Kinetics of Small Molecule Inhibitors of Galectin-1 Using Surface Plasmon Resonance
Preprints.org·2024· 2 citedOpen Access
Discovery of Selective and Orally Available Galectin-1 Inhibitors
Journal of Medicinal Chemistry·2023· 19 citedOpen Access
Defining the mechanism of galectin-3-mediated TGF-β1 activation and its role in lung fibrosis
2023· 1 citedOpen Access
1460P GALLANT-1: GB1211 galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC)
Annals of Oncology·2023· 1 citedOpen Access
Galectin-3: therapeutic targeting in liver disease
Expert Opinion on Therapeutic Targets·2023· 37 citedOpen Access
Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1
Frontiers in Immunology·2023· 29 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Alison C. MacKinnon(10), Ulf J. Nilsson(7), Fredrik R. Zetterberg(7), James A. Roper(6), Anders N. Pedersen(6), Hakon Leffler(6), David A. Hall(6), Simon T. Hodgson(6), Panayiotis A. Procopiou(6), Hans Schambye(5), Pauline T. Lukey(5), Richard P. Marshall(5), Alison J. Ford(5), K. R. H. Wooldridge(5), Simon J. F. Macdonald(4), Lise Gravelle(4), Ross Mills(4), John W. Barrett(4), Steven L. Sollis(4), Gísli Jenkins(3)